×
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
NYSE:DGX

Quest Diagnostics Stock Forecast, Price & News

$137.61
+1.15 (+0.84%)
(As of 06/29/2022 04:00 PM ET)
Add
Compare
Today's Range
$135.48
$138.40
50-Day Range
$127.07
$145.39
52-Week Range
$125.33
$174.16
Volume
577,640 shs
Average Volume
1.18 million shs
Market Capitalization
$16.15 billion
P/E Ratio
9.16
Dividend Yield
1.91%
Price Target
$150.33
30 days | 90 days | 365 days | Advanced Chart

Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Stock Forecast (MarketRank)

Overall MarketRank

2.51 out of 5 stars

Medical Sector

62nd out of 1,432 stocks

Medical Laboratories Industry

2nd out of 32 stocks

Analyst Opinion: 1.2Community Rank: 3.5Dividend Strength: 4.2Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
Quest Diagnostics logo

About Quest Diagnostics (NYSE:DGX)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

DGX Stock News Headlines

Quest Diagnostic Stock is Ready to Move Higher
Medical diagnostic lab company Quest Diagnostic (NYSE: DGX) stock has been performing relatively stronger than the benchmark indices down only (-20%) on the year.
Quest Diagnostics (NYSE:DGX) Lowered to Hold at StockNews.com
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
74834L10
Employees
49,000
Year Founded
1967

Company Calendar

Ex-Dividend for 4/20 Dividend
4/05/2022
Dividend Payable
4/20/2022
Last Earnings
4/21/2022
Today
6/29/2022
Ex-Dividend for 7/20 Dividend
7/05/2022
Dividend Payable
7/20/2022
Next Earnings (Confirmed)
7/21/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$150.33
High Stock Price Forecast
$170.00
Low Stock Price Forecast
$129.00
Forecasted Upside/Downside
+9.2%
Consensus Rating
Hold
Rating Score (0-4)
2.3
Research Coverage
10 Analysts

Profitability

Net Income
$2.00 billion
Pretax Margin
22.71%

Debt

Sales & Book Value

Annual Sales
$10.79 billion
Cash Flow
$17.87 per share
Book Value
$52.85 per share

Miscellaneous

Free Float
115,370,000
Market Cap
$16.15 billion
Optionable
Optionable
Beta
1.05

Social Links















Quest Diagnostics Frequently Asked Questions

Should I buy or sell Quest Diagnostics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Quest Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View analyst ratings for Quest Diagnostics
or view top-rated stocks.

What is Quest Diagnostics' stock price forecast for 2022?

10 brokerages have issued 12 month price targets for Quest Diagnostics' shares. Their DGX stock forecasts range from $129.00 to $170.00. On average, they anticipate Quest Diagnostics' stock price to reach $150.33 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for Quest Diagnostics
or view top-rated stocks among Wall Street analysts.

How has Quest Diagnostics' stock price performed in 2022?

Quest Diagnostics' stock was trading at $173.01 at the beginning of the year. Since then, DGX stock has decreased by 20.5% and is now trading at $137.61.
View the best growth stocks for 2022 here
.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, July 21st 2022.
View our earnings forecast for Quest Diagnostics
.

How can I listen to Quest Diagnostics' earnings call?

Quest Diagnostics will be holding an earnings conference call on Thursday, July 21st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) announced its earnings results on Thursday, April, 21st. The medical research company reported $3.22 earnings per share for the quarter, beating analysts' consensus estimates of $2.91 by $0.31. The medical research company had revenue of $2.61 billion for the quarter, compared to the consensus estimate of $2.64 billion. Quest Diagnostics had a trailing twelve-month return on equity of 27.08% and a net margin of 17.61%. Quest Diagnostics's revenue was down 4.0% on a year-over-year basis. During the same period last year, the firm earned $3.76 earnings per share.
View Quest Diagnostics' earnings history
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Tuesday, May 17th. Shareholders of record on Wednesday, July 6th will be given a dividend of $0.66 per share on Wednesday, July 20th. This represents a $2.64 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date of this dividend is Tuesday, July 5th.
View Quest Diagnostics' dividend history
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics(NYSE:DGX) pays an annual dividend of $2.64 per share and currently has a dividend yield of 1.91%. Quest Diagnostics has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Quest Diagnostics is 17.58%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 31.88% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.
View Quest Diagnostics' dividend history.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics announced that its board has approved a share buyback plan on Thursday, February 4th 2021, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 6.1% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's leadership believes its stock is undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY22 earnings guidance on Thursday, April, 21st. The company provided earnings per share guidance of $9.00-9.50 for the period, compared to the consensus EPS estimate of $8.98. The company issued revenue guidance of $9.2-9.5 billion, compared to the consensus revenue estimate of $9.35 billion.

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics CEO Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among Quest Diagnostics' employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $137.61.

How much money does Quest Diagnostics make?

Quest Diagnostics (NYSE:DGX) has a market capitalization of $16.15 billion and generates $10.79 billion in revenue each year. The medical research company earns $2.00 billion in net income (profit) each year or $15.019990 on an earnings per share basis.

How many employees does Quest Diagnostics have?

Quest Diagnostics employs 49,000 workers across the globe.

Does Quest Diagnostics have any subsidiaries?

The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).
Read More

When was Quest Diagnostics founded?

Quest Diagnostics was founded in 1967.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The official website for Quest Diagnostics is www.questdiagnostics.com. The medical research company can be reached via phone at (973) 520-2700, via email at [email protected], or via fax at 201-462-4169.

This page (NYSE:DGX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.